Karyopharm Therapeutics
http://www.karyopharm.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Karyopharm Therapeutics
Without An Alzheimer’s Blockbuster, Biogen Is A Ship Without A Growth Rudder
In addition to its uncertain attempt at near-term revenue growth with Eisai-partnered lecanemab, Biogen recently ended multiple R&D programs and will pay $900m to settle a whistleblower lawsuit.
Deal Watch: Iktos Doubles Its 2022 Alliance Tally In Agreements With Galapagos, Zealand
French AI-driven drug design firm will employ multiple technology platforms in latest tie-ups. Apellis looks to augment Empaveli-led portfolio in C3 complement R&D alliance with Affilogic.
Xpovio’s Solid Tumor Debut Faces Likely Three-Year Delay
Karyopharm will conduct another trial of the drug in p53 wild-type endometrial cancer after the FDA said SIENDO data were insufficient for approval.
Subgroup Could Give Xpovio Focused Commercial Opportunity In Endometrial Cancer
Karyopharm’s Phase III SIENDO study showed what analysts called a “modest” progression-free survival improvement overall, but a fourfold improvement in patients with wild-type p53.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- NPM Pharma, Inc.